Synonym
Piposulfan; A-20968; A20968; A 20968; Ancyte
IUPAC/Chemical Name
Piperazine, 1,4-bis(3-((methylsulfonyl)oxy)-1-oxopropyl)-
InChi Key
NUKCGLDCWQXYOQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C12H22N2O8S2/c1-23(17,18)21-9-3-11(15)13-5-7-14(8-6-13)12(16)4-10-22-24(2,19)20/h3-10H2,1-2H3
SMILES Code
O=C(N1CCN(C(CCOS(=O)(C)=O)=O)CC1)CCOS(=O)(C)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
386.43
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Merisko-Liversidge E, Sarpotdar P, Bruno J, Hajj S, Wei L, Peltier N, Rake J, Shaw JM, Pugh S, Polin L, Jones J, Corbett T, Cooper E, Liversidge GG. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res. 1996 Feb;13(2):272-8. PubMed PMID: 8932448.
2: Polin L, Valeriote F, White K, Panchapor C, Pugh S, Knight J, LoRusso P, Hussain M, Liversidge E, Peltier N, Golakoti T, Patterson G, Moore R, Corbett TH. Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. Invest New Drugs. 1997;15(2):99-108. PubMed PMID: 9220288.
3: Yellin TO. Effects of piposulfan (Ancyte) on protein and DNA synthesis in Ehrlich ascites carcinoma. Life Sci II. 1971 Jun 8;10(11):605-12. PubMed PMID: 5556760.
4: Wilson HE, Monto RW, Pisciotta AV, Rohn RJ, Louis J. Treatment of chronic granulocytic leukemia with piposulfan (NSC-47774). Cancer Chemother Rep. 1969 Apr;53(2):121-6. PubMed PMID: 5256921.
5: Kenis Y. [Effect of piposulfan (ancyte) in malignant lymphomas and solid tumors]. Acta Clin Belg. 1968;23(2):103-13. French. PubMed PMID: 4914032.
6: Nelson NA, Talley RW, Reed ML, Evans AM, Isaacs BL, Huffman P, Louis J. Midwest cooperative group evaluation of piposulfan (A-20968) in cancer. Clin Pharmacol Ther. 1967 May-Jun;8(3):385-91. PubMed PMID: 5338383.
7: Senning A, Buchholt HC, Bierling R. [Novel Bis-sulfonic Acid Esters with Cytostatic Activity (author's transl)]. Arzneimittelforschung. 1976;26(10):1800-9. German. PubMed PMID: 191037.
8: Kenis Y. Effect of piposulfan (NSC-47774) on malignant lymphomas and solid tumors. Cancer Chemother Rep. 1968 Apr;52(3):433-9. PubMed PMID: 5244316.
9: Schmidt M, Havemann K. [Treatment of chronic myeloid leukemia and lymphoreticular sarcoma with piposulfan]. Dtsch Med Wochenschr. 1970 May 22;95(21):1166-70. German. PubMed PMID: 4910386.
